Navigation Links
Avanir Pharmaceuticals Reports Fiscal 2013 Second Quarter Financial and Business Results

,009TOTAL ASSETS$  85,710,685$   86,011,796LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Accounts payable, accrued expenses and other liabilities

$  20,734,658$   15,598,666Current portion of note payable

7,812,0142,162,263Current portion of deferred royalty revenues

2,557,4642,557,464Total current liabilities

31,104,13620,318,393Accrued expenses and other liabilities, net of current portion

1,073,265666,179Note Payable

21,325,05526,698,263Deferred royalty revenues, net of current portion

117,0221,491,854Total liabilities

53,619,47849,174,689Total stockholders' equity

32,091,20736,837,107TOTAL LIABILITIES AND STOCKHOLDERS'  EQUITY$  85,710,685$   86,011,796 AVANIR PHARMACEUTICALS, INC.CONDENSED STATEMENT OF OPERATIONSThree Months Ended March 31,Six Months Ended March 31,2013201220132012REVENUESNet product sales

$  16,535,059$
9,141,873$   31,414,321$   14,630,636Revenues from royalties

899,129898,5152,525,1392,574,635Revenue from research grant services

--15,000-Total revenues

17,434,18810,040,38833,954,46017,205,271OPERATING EXPENSESCost of product sales

933,426534,3451,771,555844,148Cost of research grant services

69,090-78,488-Research and development

8,874,2986,395,15515,522,38910,139,670Selling and marketing

16,061,40814,814,01329,583,82728,596,850General and administrative

6,978,6845,346,99113,517,08710,639,173Total operating expenses

32,916,90627,090,50460,473,34650,219,841Loss from operations(15,482,718)(17,050,116)(26,518,886)(33,014,570)OTHER INCOME (EXPENSE)Interest income

15,0657,88234,39622,173Interest expense

(1,059,245)-(2,118,490)-Other, net

197751974,081Loss before provision for income taxes(16,526,701)(17,042,159)(28,602,783)(32,988,316)Provision for income taxesNet loss and comprehensiv

SOURCE Avanir Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Avanir Pharmaceuticals Announces Date of Fiscal 2013 Second Quarter Financial Results and Conference Call
2. Avanir Pharmaceuticals Receives Positive CHMP Opinion for Approval of NUEDEXTA in Europe
4. AVANIR Pharmaceuticals To paticipate in two conferences in March
5. Avanir Pharmaceuticals Reports Fiscal 2013 First Quarter Financial And Business Results
6. Avanir Pharmaceuticals Announces Positive Interim Data From Pharmacokinetic Study With Next Generation Compound AVP-786
7. Avanir Pharmaceuticals Announces Date Of Fiscal 2013 First Quarter Financial Results And Conference Call
8. Avanir Pharmaceuticals Reports Fiscal 2012 Fourth Quarter And Year-End Financial And Business Results
9. Avanir Pharmaceuticals Pre-Announces Preliminary Fiscal 2012 Fourth Quarter Results And Provides Clinical Study Update
10. Avanir Pharmaceuticals To Present At 24th Annual Piper Jaffray Healthcare Conference
11. Avanir Pharmaceuticals Achieves Commercial Milestones & Provides Clinical Updates
Post Your Comments:
(Date:10/8/2015)...  Trovagene, Inc., (NASDAQ:   TROV) a developer ... of results from a field experience analysis featuring ... (PCM) platform to accurately identify mutational status, ... appropriate therapy for patients. Mark Erlander , ... the results today in an oral presentation titled ...
(Date:10/8/2015)... October 8, 2015 " Biomedical ... Growth, Trends and Forecast 2014 - 2022 " , ... 2.63 billion in 2013 and is anticipated to expand at ... USD 4.00 billion in 2022. --> " ... Share, Growth, Trends and Forecast 2014 - 2022 " ...
(Date:10/8/2015)... , Oct. 08 2015 ... addition of the "Natural Language Processing ... Industry by Type (Rule-Based, Statistical, & Hybrid ... Middle East and Africa, Latin America) - ... their offering. --> ) ...
Breaking Medicine Technology:
... The U.S. Food and Drug Administration today announced that monthly ... Letairis tablets (ambrisentan), used to treat high blood pressure in ... hypertension, or PAH). (Logo: ) ... the FDA said that the drug poses only a low ...
... 4, 2011 Sigma-Aldrich Corporation (Nasdaq: SIAL ) ... 31st Annual Cowen and Company Healthcare Conference ... Place, Boston, MA, presenting at 10:15 AM (EST). Barclays ... the Loews Miami Hotel, Miami, FL, presenting at 10:15 AM ...
Cached Medicine Technology:
(Date:10/9/2015)... ... October 09, 2015 , ... Head Over Heels Athletic Arts gymnast, ... camp at the Karolyi Ranch in Huntsville, Texas on October 17-21. , "It's ... girls team head coach and executive director, said. “It's a stepping stone into the ...
(Date:10/9/2015)... ... October 09, 2015 , ... On Saturday, September 26, 2015, 48-year-old ... Championship in Madrid, Spain. Representing both the USA and Sweden in the Speed and ... One-Minute Am Front Crosses, she was awarded 1 Silver and 4 Gold Medals. , ...
(Date:10/9/2015)... ... October 09, 2015 , ... ... “Agents of Change” program, a community improvement initiative that involves working with a ... benefit from the assistance of Confidence Plus Insurance is the Gleason Park Electric ...
(Date:10/9/2015)... PA (PRWEB) , ... October 09, 2015 , ... "As ... of two inventors from Philadelphia, Pa. "They have to wear large diapers or pads. ... solutions." , They developed the TROUSAFE to absorb urine leaking from the tip of ...
(Date:10/9/2015)... ... October 09, 2015 , ... MMJ PhytoTech Limited announced ... Begley Jr., airing 1st QT 2016 via the Discovery Channel. Dates and show ... Limited (MMJ) – a global leader in the field of commercializing medicinal grade ...
Breaking Medicine News(10 mins):
... mutate for a living, evading antibiotic drugs while killing tens ... But as concern about drug-resistant bacteria grows, one novel approach ... Hill seeks to thwart the bug without a drug by ... his lab of analytical chemists at UNC have created nano-scale ...
... Fourth Quarter 2007 Revenue Increases 32% to $14.2 Million ... Profit Margin at 58.2% Sets Quarterly Record, MINNEAPOLIS, Feb. ... marketer of state-of-the-art cardiac,surgery products and services, today reported financial ... 2007. Revenue for the,quarter was $14.2 million, up 32.4% from ...
... effectiveness of these breast cancer detection methods, study says ... combined hormone therapy for about five years have a higher ... turn, may decrease the effectiveness of these methods of detecting ... Feb. 25 issue of Archives of Internal Medicine . ...
... Aram,will lend his support to another noteworthy cause, The Naz ... flagship store on March,13th for a special benefit event., ... charity that was,established in 1994, at a time when the ... itself to raising awareness on and,preventing the local spread of ...
... Influenza and ... MRSA., ... SEAL(TM) Washable, Antimicrobial Mouse at the HiMSS,Healthcare Symposium in Orlando, FL. According ... to be fully submersible,dishwasher safe, and manufactured from SILVER SEAL(TM) Antimicrobial,plastic. The ...
... Feb. 25 The Quantum Group,Inc. (Amex: QGP, ... J. Guillama, President & CEO, will present at ... Thursday, February 28, 2008, which will,be held at ... The presentations will be held in the Grand ...
Cached Medicine News:
... Anatomical Malar I Implants - Providing the ... follows the contour of the zygoma while ... Anatomical Malar II Implants - The ... surgeon with another augumentation option that adds ...
Chin Implants are used for cosmetic augmentation, repairing trauma related injuries and genetic deficiencies. They are inserted through an incision in the mouth below the incisor teeth or through an ...
... FL40 Centrifuge Series from Thermo Electron ... increase your productivity in the lab. ... rotors and accessories for high-volume blood ... IEC CL40 and FL40 Centrifuge Series ...
Medicine Products: